• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BNT162b2 XBB疫苗对XBB和JN.1亚谱系的有效性。

Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages.

作者信息

Tartof Sara Y, Slezak Jeff M, Puzniak Laura, Frankland Timothy B, Ackerson Bradley K, Jodar Luis, McLaughlin John M

机构信息

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.

Global Vaccines and Antivirals, Pfizer Inc, Collegeville, Pennsylvania, USA.

出版信息

Open Forum Infect Dis. 2024 Jul 1;11(7):ofae370. doi: 10.1093/ofid/ofae370. eCollection 2024 Jul.

DOI:10.1093/ofid/ofae370
PMID:39015348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11250225/
Abstract

We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.

摘要

我们提供了之前在南加州凯撒医疗集团进行的检测阴性病例对照研究的最新结果（2023年10月11日至2024年2月29日），以评估BNT162b2 XBB1.5适配疫苗针对特定亚谱系的有效性。结果表明，与XBB亚谱系相比，XBB1.5适配疫苗对JN.1的有效性可能降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/11250225/82511aeef7ff/ofae370f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/11250225/c240ff5f4738/ofae370f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/11250225/82511aeef7ff/ofae370f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/11250225/c240ff5f4738/ofae370f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4d1/11250225/82511aeef7ff/ofae370f2.jpg

相似文献

1
Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages.BNT162b2 XBB疫苗对XBB和JN.1亚谱系的有效性。
Open Forum Infect Dis. 2024 Jul 1;11(7):ofae370. doi: 10.1093/ofid/ofae370. eCollection 2024 Jul.
2
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.BNT162b2 BA.4/5 二价 mRNA 疫苗在美国大型医疗体系中针对一系列 COVID-19 结局的有效性：一项病例对照研究。
Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25.
3
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.单价奥密克戎XBB.1.5适应性BNT162b2新冠疫苗针对XBB.1.5、BA.2.86和JN.1亚谱系的免疫原性：一项2/3期试验
Vaccines (Basel). 2024 Jul 2;12(7):734. doi: 10.3390/vaccines12070734.
4
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.2023 - 2024年更新的（单价XBB.1.5）新冠疫苗针对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系预防住院的有效性及临床严重程度比较 - IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Clin Infect Dis. 2024 Aug 6. doi: 10.1093/cid/ciae405.
5
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.2023 - 2024年更新的（单价XBB.1.5）新冠疫苗针对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系预防住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日至2024年3月9日
medRxiv. 2024 Jun 5:2024.06.04.24308470. doi: 10.1101/2024.06.04.24308470.
6
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.早期估计，二价 mRNA 加强针在预防免疫功能正常成年人因奥密克戎 BA.5-和 XBB/XBB.1.5 相关亚谱系导致的有症状 SARS-CoV-2 感染方面的有效性-增加社区获得检测计划，美国，2022 年 12 月至 2023 年 1 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.
7
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.mRNA-1273 BA.4/BA.5 二价疫苗（mRNA-1273.222）对 SARS-CoV-2 BA.4/BA.5 和 XBB 亚谱系的有效性和持久性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2335052. doi: 10.1080/21645515.2024.2335052. Epub 2024 Apr 4.
8
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.单价奥密克戎XBB.1.5适配的BNT162b2新冠疫苗在12岁及以上人群中的安全性和免疫原性：一项2/3期试验
Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118.
9
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.奥密克戎 XBB.1.5 疫苗对感染 SARS-CoV-2 奥密克戎 XBB 和 JN.1 变异株的有效性，前瞻性队列研究，荷兰，2023 年 10 月至 2024 年 1 月。
Euro Surveill. 2024 Mar;29(10). doi: 10.2807/1560-7917.ES.2024.29.10.2400109.
10
Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.对 BNT162b2 二价加强针接种后六个月时针对 XBB.1.5、BA.2.86、FL.1.5.1 和 JN.1 的中和抗体反应。
Int J Infect Dis. 2024 Jun;143:107028. doi: 10.1016/j.ijid.2024.107028. Epub 2024 Apr 5.

引用本文的文献

1
Real-World Effectiveness of Boosting Against Omicron Hospitalization in Older Adults, Stratified by Frailty.在老年人中，根据虚弱程度分层，加强免疫对预防奥密克戎感染导致住院的实际效果。
Vaccines (Basel). 2025 May 26;13(6):565. doi: 10.3390/vaccines13060565.
2
Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up.单价mRNA XBB.1.5疫苗对加拿大魁北克省COVID-19住院治疗的有效性：10个月随访期间变异株替代和保护作用减弱的影响。
PLoS One. 2025 Jun 3;20(6):e0325269. doi: 10.1371/journal.pone.0325269. eCollection 2025.
3

本文引用的文献

1
Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19.BNT162b2 XBB 疫苗对 COVID-19 的估计有效性。
JAMA Intern Med. 2024 Aug 1;184(8):932-940. doi: 10.1001/jamainternmed.2024.1640.
2
Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine.2023-2024 年 COVID-19 mRNA 疫苗配方的有效性。
Clin Infect Dis. 2024 Aug 16;79(2):405-411. doi: 10.1093/cid/ciae132.
3
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.
Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity.
开发用于广泛的沙贝病毒免疫的二价RBD适应性新冠疫苗。
NPJ Vaccines. 2025 May 29;10(1):108. doi: 10.1038/s41541-025-01156-3.
4
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.2023年11月至2024年5月在欧洲VEBIS医院进行的研究：XBB.1.5新冠疫苗在BA.2.86/JN.1为主导的时期对≥65岁成年人预防新冠病毒住院治疗的有效性
Influenza Other Respir Viruses. 2025 Mar;19(3):e70081. doi: 10.1111/irv.70081.
5
XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants.XBB.1.5 mRNA新冠疫苗对感染SARS-CoV-2 JN.1和XBB谱系变体的成年人住院或急诊就诊的防护作用。
Front Immunol. 2025 Feb 17;16:1470609. doi: 10.3389/fimmu.2025.1470609. eCollection 2025.
6
Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform.BNT162b2 XBB.1.5 适配疫苗对欧洲与JN.1变体相关的新冠病毒住院治疗的有效性：一项使用id.DRIVE平台的检测呈阴性病例对照研究。
EClinicalMedicine. 2024 Dec 9;79:102995. doi: 10.1016/j.eclinm.2024.102995. eCollection 2025 Jan.
XBB.1.5 单价 mRNA 疫苗加强针可诱导针对 XBB 亚谱系和 JN.1 的强大中和抗体。
Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. doi: 10.1016/j.chom.2024.01.014. Epub 2024 Feb 19.
4
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.2023-2024 年（单价 XBB.1.5）更新 COVID-19 疫苗对免疫功能正常成年人中共同流行的奥密克戎变异株引起的有症状 SARS-CoV-2 感染的有效性的早期估计——增加社区获得检测计划，美国，2023 年 9 月至 2024 年 1 月。
MMWR Morb Mortal Wkly Rep. 2024 Feb 1;73(4):77-83. doi: 10.15585/mmwr.mm7304a2.
5
Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.XBB.1.5更新的新冠疫苗对丹麦住院治疗的短期有效性：一项全国队列研究
Lancet Infect Dis. 2024 Feb;24(2):e73-e74. doi: 10.1016/S1473-3099(23)00746-6. Epub 2024 Jan 5.
6
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023.2023 年 10 月 9 日至 12 月 5 日，荷兰针对 XBB.1.5 的 COVID-19 疫苗对住院和入住重症监护病房的早期有效性。
Euro Surveill. 2024 Jan;29(1). doi: 10.2807/1560-7917.ES.2024.29.1.2300703.
7
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.在强大免疫压力下，新冠病毒BA.2.86快速进化为JN.1 。
Lancet Infect Dis. 2024 Feb;24(2):e70-e72. doi: 10.1016/S1473-3099(23)00744-2. Epub 2023 Dec 15.
8
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.BNT162b2 BA.4/5 二价 mRNA 疫苗在美国大型医疗体系中针对一系列 COVID-19 结局的有效性：一项病例对照研究。
Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25.
9
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5.BNT162b2疫苗对新冠病毒奥密克戎BA.4和BA.5的有效性
Lancet Infect Dis. 2022 Dec;22(12):1663-1665. doi: 10.1016/S1473-3099(22)00692-2. Epub 2022 Oct 25.